Leishmaniasis is a globally neglected infectious disease that is caused by protozoan parasites. The treatment of leishmaniasis is constrained and frequently associated with serious side effects. Amphotericin B is a highly effective anti-leishmanial drug; however, its oral administration is restricted by its low bioavailability and toxicity. To address this problem, a novel formulation, VitB12-PEG4000-AmB-CNFs, was developed for oral delivery of AmB. The formulation showed a particle size of 490 nm with a surface charge of 28.53, and the BET surface area of the CNFs was 42.08 m2/g facilitated drug loading capacity. FTIR and XRD confirmed the functionalization, loading of the drug, and encapsulation of the conjugates. The formulation was observed in SEM images with irregular surface and multi-layered functionalization of VitB12-PEG4000 conjugates on AmB-CNFs, supporting that EDS spectra showed an increase in the% weight of N. VitB12-PEG4000-AmB-CNFs showed strong anti-leishmanial activity against Leishmania donovani intramacrophage amastigotes while minimizing cytotoxicity to host cells. This innovative approach presents a promising therapeutic alternative, combining targeted delivery with reduced side effects to effectively address the persistent challenges in treating leishmaniasis